Background: Limited information is available regarding neurocognitive outcomes of children who experience seizures during treatment for acute lymphoblastic leukemia (ALL). Accordingly, the main objectives of this study were to determine the incidence and risk factors for treatmentrelated seizures among children with ALL, and the neurocognitive outcomes associated with treatment-related seizures.
INTRODUCTION
Advancements in systemic and central nervous system (CNS) directed treatment have dramatically enhanced 5-year survival rates of children with acute lymphoblastic leukemia (ALL), the most common childhood cancer, to over 90% in several contemporary clinical trials. 1 However, Wechsler Individual Achievement Test; WISC-III, Wechsler Intelligence Scale for ChildrenThird Edition; WPPSI-R, Wechsler Preschool and Primary Scale of Intelligence -Revised up to 20% of the patients still receive prophylactic cranial irradiation (CRT), which results in cognitive late effects in approximately 60% of survivors. 2, 3 Risk factors associated with cognitive function decline include younger age at diagnosis, female gender, greater time since treatment, and higher treatment intensity. [4] [5] [6] [7] [8] Younger developing brains appear vulnerable to therapy-related neurotoxicity, as evidenced by decreased cerebral white matter volumes and increased oxidative stress in the CNS after treatment. 9 Additionally, women may be particularly vulnerable to CNS-directed therapy, as men's neurodevelopment involves greater white matter volume increases in childhood. 10 Although elimination of CRT has reduced overall cognitive impairment in ALL survivors, intensive systemic and intrathecal chemotherapy to offset the removal of CRT can also cause impairment of acute and long-term neurocognitive outcomes and quality of life. 4 Reviews and meta-analyses of the late effects of CNS-directed chemotherapy in ALL survivors suggest that contemporary treatment negatively affects several domains of cognitive function. [5] [6] [7] [11] [12] [13] Among leukemia survivors, attention and working memory deficits predominate in subtle yet significant ways that impact daily life. 8, 14 Attention deficits in ALL survivors have been linked to smaller and abnormal cerebral white matter volumes. 15 Additionally, working memory assessment appears useful in detecting treatment-related cognitive changes, as those measurements are sensitive to cognitive decline in patients treated without CRT and have been shown to predict overall intelligence scores. 14 Detecting chemotherapy-related declines in specific cognitive abilities is necessary to develop targeted interventions and assist in the confirmation of neural pathways hypothesized to be directly related to cognitive deficits. 4 While CRT, with and without chemotherapy, has been strongly linked to intracranial white matter changes, vascular damage, and other neuropsychological and neuroendocrine issues, chemotherapy alone has also been associated with significant neurocognitive side effects. 5 Leukoencephalopathy, as measured by magnetic resonance imaging (MRI), can be found in as many as 86% of the patients treated with seven courses of intravenous high-dose methotrexate (HDMTX). 16 At the end of treatment, MTX therapy has been associated with abnormal frontal lobe white matter and working memory deficits, yet the long-term effects related to these changes are not clear. 14, 16, 17 Intensive CNS-directed treatment can cause homocysteine excitotoxicity and neuronal death, which may clinically present as focal neurological deficits, stroke-like episodes, or seizures. 12, 18 Despite anti-inflammatory properties, glucocorticoids such as dexamethasone and prednisone used in the treatment for ALL may also result in neuronal death and seizure. 19 Approximately 3-13% of children experience seizure during treatment for ALL. [20] [21] [22] [23] [24] [25] [26] Higher doses of intrathecal and intravenous MTX have been identified as a risk factor for seizure. 25 In a study of 384 pediatric cancer patients, seizure occurred in 47 children, of whom 16 were treated for ALL. 27 Seizure risk was higher for younger children (≤10 years), boys, and patients with ALL. 27 Treatment-related seizures generally developed within the first 6 weeks of therapy during remission induction and consolidation treatment. 21, 28, 29 Among children with CNS relapse who experienced seizure, Mulhern et al. 30 found weak negative correlations between seizures and overall cognitive and academic performance. Computed tomography scans of four children with ALL hospitalized for seizures after treatment with high-dose intravenous and intrathecal chemotherapy revealed diffuse periventricular white matter hypodensities and three of them showed subcortical hyperdense foci. 31 In all four cases, MRI revealed diffuse hyperintense white matter lesions on T2-weighted images. The authors concluded that the white matter lesions with calcification were related to leukoencephalopathy and resultant seizures. 31 Otherwise, little is known about neurocognitive changes, psychosocial outcomes, or diagnostic imaging findings of ALL survivors who experience on-therapy seizures. The current study was conducted to address this gap in the literature.
The first study objective was to estimate the risk of seizure in children treated for ALL and identify demographic and/or clinical factors associated with seizure risk. Given the omission of CRT on the TOTXV protocol, we predicted that seizure occurrence would be in the lower range as reported in the literature (roughly 5%). We also predicted that treatment intensity and premorbid seizure history would be seizure risk factors. The second objective was to assess neurocognitive changes in children with on-therapy seizures by comparing serial neuropsychological assessment across three time points. Children with on-therapy seizures were predicted to have worsening cognitive 
METHODS

Patients and setting
Patients included children (N = 498) with newly diagnosed ALL sequentially enrolled on St. Jude Total Therapy XV protocol (TOTXV, clinicaltrials.gov identifier NCT00137111) of whom a subset of 57 participants were the focus of this seizure-related study. The TOTXV protocol was designed to test whether prophylactic CRT could be safely omitted from treatment of all children with ALL. 32 Based on presenting genetic features and early treatment response, as measured by minimal residual disease during remission induction, children were assigned to low-risk or standard/high-risk groups, with increased treatment intensity for the standard/high-risk arm across remission induction, consolidation, and continuation phases. 32 Depending on presenting characteristics and leukemic cell counts in the cerebrospinal fluid, patients with low-risk ALL received 13-18 intrathe- 
Intellectual functioning
Age-appropriate intelligence tests were utilized, including the Wechsler Scale (WAIS-III for age > 16 years, WISC-III for age [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] years, WPPSI-R for age < 6 years) and Bayley Scale (BSID for age < 2 years). [33] [34] [35] [36] Wechsler and Bayley scores have an age standardized mean score of 100 and standard deviation of 15. Estimated Intelligence Quotient (EIQ) scores were obtained at all assessment time points.
Full-Scale Intelligence Quotient (FSIQ) scores were obtained at the latter two assessments. EIQ was calculated from the Information, Similarities, and Block Design subtests using a formula provided in Sattler, 37 which highly correlates with FSIQs (r = 0.93).
Academic achievement
Academic skills were assessed for children at least 6 years of age using the Word Reading and Math Reasoning subtests from the Wech- 
Attention, working memory, and processing speed
Children between the ages of 6 and 16 were administered the WISC- 
Parental report of behavioral problems and attention abilities
Behavioral problems and inattention symptoms were assessed using the Learning, Psychosomatic, Impulsive-Hyperactive, and Hyperactive subscales of the Conners Parent Rating Scale (CPRS 40 ). Parents rated each item on a scale of 0 "Not True At All" to 3 "Very Much True," in regard to the intensity of the behavior problem in the past month.
CPRS subscales are age and gender standardized, with a T-score (M = 50, SD = 10).
Leukoencephalopathy
MRI examinations were classified as either normal appearing white matter or leukoencephalopathy by a neuroradiologist (F.H.L.) who was blinded to neuropsychological assessment and treatment risk arm.
Images were acquired using a 1. = 300 ms; seven echoes). T2/proton-density weighted images were obtained using a dual spin-echo sequence (TR/TE1/TE2 = 3,500/17/102 ms, five echoes). Fluid-attenuated inversion recovery images were acquired with a multi-echo inversion recovery sequence (TR/TE/TI = 9,000/119/2470 ms; seven echoes).
Statistical analyses
Of the 498 children on protocol, 19 experienced on-therapy seizures, which was defined as at least one incident of Grade 2 or higher seizure (i.e., altered consciousness). To increase the statistical power of comparisons, each of the 19 children were matched to two children on the TOTXV protocol without seizure experience (n = 57). Matching variables included gender, race, age at treatment, and treatment intensity. Measurements included neuropsychological and neuroimaging examinations across three time points. Neuropsychological assessments were conducted after one dose of HDMTX (week 6 induction), at the end of therapy (week 120 continuation end -no intrathecal therapy for approximately 72 weeks, no HDMTX for approximately 120 weeks, no corticosteroids for approximately 20 weeks), and at 2 years after therapy completion. MRI examinations were conducted after one dose of HDMTX (week 5 induction), after five doses of HDMTX (week 7 continuation), and at the end of therapy (week 120 continuation end)
To characterize the sample and ensure group equivalence, qualitative analyses of demographic and clinical variables were performed.
Cumulative incidence was utilized to estimate the rate of seizure occurrence and identify factors associated with seizure risk. The cumulative incidence of seizure (i.e., first event) was tested between groups by using the method described by Gray 41 and the estimation was produced by using the method described by Kalbfleisch and Prentice. 42 One-way repeated measures analysis of variance 
RESULTS
For the entire TOTXV sample of 498 patients, the estimated cumulative incidence rates of Grade 2 or higher seizures were 3.21 ± 0.79% at 1 year and 3.82 ± 0.86% at 2 years (Fig. 2) . Additionally, age at diagnosis, race, and gender did not have a statistically significant effect on seizure development. Of the 19 children with treatment-related seizures, two had a prior history of seizures. However, this relationship was not statistically significant, likely due to reduced power secondary to small sample size. Treatment intensity was trending toward statistical significance, with the standard/high-risk group having a higher estimated incidence rate of seizures than the low-risk group (2-year cumulative risk, 5.6 ± 1.6 vs. 2.5 ± 0.9, respectively, P = 0.06). Induction and consolidation phases had the highest frequency of seizure onset, each at 26%, accounting for over half of on-therapy seizures (Supplementary Table S1 for additional information on seizure onset, frequency, and severity).
F I G U R E 2 Cumulative incidence of Grade 3 or higher seizure on TOTXV. Note: Estimated 1-and 2-year cumulative incidence rates of Grade 3 (i.e., altered consciousness) and higher seizures were 3.21 ± 0.79% and 3.82 ± 0.86%, respectively, for the entire TOTXV sample
For the subsample of 57 children, there were no significant differences between the seizure group and the control group with respect to age, race, gender, or treatment intensity (Table 1) . Ages ranged from 2 to 18 years, with a mean age of 8.2 years across groups. There were no significant differences in dosing (mg/m 2 ) of dexamethasone, HDMTX, and intrathecal therapy (hydrocortisone, MTX, and Ara-C) between the two groups.
Neurocognitive outcomes
Among the seizure group, basic reading scores significantly declined from first assessment to 2 years after therapy completion (MD = -6.77 points, P = 0.05; Table 2 ). However, parental report of learning problems as measured by Conners indicated significant improvement from first assessment to 2 years after therapy (MD = -19.27 points, P = 0.01).
In contrast to hypotheses, significant change was not observed for estimated intellectual functioning (EIQ), attention, working memory, processing speed, math reasoning, or other behavioral problems from initial assessment to 2 years after therapy.
In comparison to published norms, at initial neuropsychological assessment, the seizure group demonstrated a significantly lower mean IQ (M = 89.33 vs. 100; P = 0.01; Note: Significant P values are asterisked, which indicate a difference between the neuropsychological performance of children with on-therapy seizures to published norms at each time point using one-sample t-tests. RT, Reaction Time. M = 80.14 vs. 100.74, P < 0.01; DS Total, M = 6.43 vs. 9.52, P = 0.05). Clinically significant differences in attention and working memory tasks, namely FFD, were evidenced after accounting for leukoencephalopathy among seizure experience (Supplementary   Table S2 Lastly, significant differences in rate of leukoencephalopathy on MRI were observed between the seizure and the control cohort groups at week 7 continuation treatment (56.25 vs. 12.90%, P < 0.01) and at the end of therapy (week 120 continuation end, 38.46 vs. 6.06%, P = 0.01). However, no significant differences were found on the initial MRI examination at week 5 induction (15.38 vs. 2.94%, P = 0.18). namely impaired attention and working memory dysfunction, in children treated for ALL. 4, 8, 14 It is possible that cognitive deficits that negatively impact alert, undistracted attention, which is required for adequate learning, may precede later declines observed in overall IQ.
DISCUSSION
Children with on-therapy seizures appeared to have experienced more significant early neurotoxicity, as evidenced by greater leukoencephalopathy on MRI than the nonseizure control cohort, which may contribute to the higher level of cognitive deficits observed. Notably, 
Limitations and future directions
One major limitation of this study is its retrospective design. A prospective, longitudinal study would allow for a more systematic investigation of the emergence of cognitive late effects, including potential mechanisms of change by closely monitoring children experiencing seizures during treatment. Additionally, the lack of correlation between parent report and performance-based measures may be one of the unfortunate yet expected drawbacks of subjective rater measures, which have been shown to exhibit low rates of sensitivity and specificity. 43 The authors acknowledge the likely overlap of seizures and leukoencephalopathy in some patients; however, our data suggest that Future studies will benefit from advanced neuroimaging, such as diffusion tensor imaging (DTI). DTI is likely to assist with early identification of subtle cerebral white matter damage by examining neural pathways associated with attention and memory (e.g., the prefrontal cortex) in relation to chemotherapy-induced neurotoxicity, impaired neuropsychological performance across treatment, and cognitive late effects in childhood cancer survivors. 44 Early identification would better inform patient treatment plans with enhanced physician insight on when regimen-related accommodations are needed, such as modifying the timing or dosing of chemotherapy administrations to minimize white matter damage or seizure risk without compromising a favorable treatment outcome.
Earlier identification of children at risk for seizure may also allow healthcare professionals to develop preventive measures against lasting therapy-related CNS impairments. For patients and their caregivers, early identification of treatment-related neurocognitive deficits may signal the need for earlier intervention focused on remedial and compensatory strategies to minimize functional impairment.
Recent empirical findings support postchemotherapy interventions that lessen cognitive late effects, 6 including both pharmacologic (e.g., methylphenidate, donepezil, modafinil) [45] [46] [47] and nonpharmacologic methods, such as therapist-delivered cognitive remediation or computerized cognitive training. [48] [49] [50] While stimulants and other pharmacologics should not be considered in patients with poorly controlled seizures, as it may be dangerous, they may be useful neuroprotective agents for patients without seizures that evidence early white matter damage on neuroimaging.
CONCLUSIONS
Despite the limitations of this study, the current findings point to a relationship between on-therapy seizures, leukoencephalopathy, and deficits in neurocognitive functioning, specifically attention, working memory, and processing speed skills, which may lead to overall declines in intellectual function. However, these findings also raise questions about the neurobehavioral mechanisms, including neuroanatomical pathways, involved in cognitive late effects associated with seizures.
Future research on theoretically driven neurobehavioral processes is necessary to unravel these mechanisms within the context of leukemia therapy so that we may improve caregiver education, treatment planning, and treatment monitoring for a growing number of survivors.
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